Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2007 | -6.57 Million USD | -32.23% |
| 2006 | -4.97 Million USD | -34.88% |
| 2005 | -3.68 Million USD | 53.18% |
| 2004 | -7.87 Million USD | -112.86% |
| 2003 | -3.69 Million USD | -150.76% |
| 2002 | -1.47 Million USD | 0.0% |
| 1999 | -2.73 Million USD | -2.23% |
| 1998 | -2.67 Million USD | -40.27% |
| 1997 | -1.91 Million USD | -53.84% |
| 1996 | -1.24 Million USD | -55.21% |
| 1995 | -800 Thousand USD | -900.0% |
| 1994 | 100 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2007 Q1 | -3.85 Million USD | -107.01% |
| 2007 FY | -6.57 Million USD | -32.23% |
| 2007 Q4 | -1.16 Million USD | -39.64% |
| 2007 Q3 | -835.76 Thousand USD | -16.64% |
| 2007 Q2 | -716.56 Thousand USD | 81.42% |
| 2006 FY | -4.97 Million USD | -34.88% |
| 2006 Q1 | -1.48 Million USD | -88.49% |
| 2006 Q3 | -787.18 Thousand USD | 5.78% |
| 2006 Q4 | -1.86 Million USD | -136.67% |
| 2006 Q2 | -835.46 Thousand USD | 43.84% |
| 2005 Q4 | -789.27 Thousand USD | -9.62% |
| 2005 Q3 | -720 Thousand USD | 28.89% |
| 2005 Q2 | -1.01 Million USD | -28.49% |
| 2005 FY | -3.68 Million USD | 53.18% |
| 2005 Q1 | -788.01 Thousand USD | 35.25% |
| 2004 Q1 | -4.27 Million USD | -244.9% |
| 2004 FY | -7.87 Million USD | -112.86% |
| 2004 Q4 | -1.21 Million USD | -22.4% |
| 2004 Q3 | -994.27 Thousand USD | 28.17% |
| 2004 Q2 | -1.38 Million USD | 67.65% |
| 2003 Q4 | -1.24 Million USD | -35.78% |
| 2003 FY | -3.69 Million USD | -150.76% |
| 2003 Q3 | -913.78 Thousand USD | -103.1% |
| 2003 Q1 | -579.69 Thousand USD | 0.0% |
| 2003 Q2 | -449.92 Thousand USD | 22.39% |
| 2002 FY | -1.47 Million USD | 0.0% |
| 2000 Q2 | -912.8 Thousand USD | 8.67% |
| 2000 Q1 | -999.42 Thousand USD | 21.17% |
| 1999 FY | -2.73 Million USD | -2.23% |
| 1999 Q4 | -1.26 Million USD | -140.89% |
| 1999 Q3 | -526.33 Thousand USD | 0.0% |
| 1998 FY | -2.67 Million USD | -40.27% |
| 1997 Q1 | -300 Thousand USD | 59.55% |
| 1997 FY | -1.91 Million USD | -53.84% |
| 1996 Q1 | 100 Thousand USD | 200.0% |
| 1996 Q2 | - USD | -100.0% |
| 1996 FY | -1.24 Million USD | -55.21% |
| 1996 Q3 | -600 Thousand USD | 0.0% |
| 1996 Q4 | -741.66 Thousand USD | -23.61% |
| 1995 Q2 | -400 Thousand USD | -300.0% |
| 1995 Q4 | -100 Thousand USD | 66.67% |
| 1995 Q3 | -300 Thousand USD | 25.0% |
| 1995 Q1 | -100 Thousand USD | 0.0% |
| 1995 FY | -800 Thousand USD | -900.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 FY | 100 Thousand USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -392.434% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 5.825% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 112.413% |
| Nascent Biotech, Inc. | -2.08 Million USD | -214.996% |
| Rebus Holdings, Inc. | -1.02 Million USD | -544.717% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 110.096% |
| Qrons Inc. | -789.34 Thousand USD | -733.108% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -939.854% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 89.495% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1482.778% |
| Skye Bioscience, Inc. | -37.64 Million USD | 82.531% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 91.228% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2305.29% |
| SQZ Biotechnologies Company | -79.46 Million USD | 91.724% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -127.359% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -261.22% |
| Mesoblast Limited | -87.95 Million USD | 92.523% |
| Marizyme, Inc. | -65.34 Million USD | 89.937% |
| Genus plc | 7.9 Million USD | 183.242% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 39.623% |
| Pharming Group N.V. | -10.54 Million USD | 37.655% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -203.073% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -77.242% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 25.643% |
| ContraFect Corporation | -65.15 Million USD | 89.907% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -34.589% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -280.682% |
| IMV Inc. | -36.48 Million USD | 81.976% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 18.407% |
| MultiCell Technologies, Inc. | -380.07 USD | -1730136.798% |
| ONE Bio Corp. | 8.67 Million USD | 175.791% |
| Accustem Sciences Inc. | -3.74 Million USD | -75.531% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 87.278% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -418.975% |
| Q BioMed Inc. | -2.05 Million USD | -220.459% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -76.162% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -176.206% |
| Biomind Labs Inc. | -1.21 Million USD | -441.547% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 88.989% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -112.012% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 16.791% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -237.366% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -43810.998% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 58.566% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -13.045% |
| GB Sciences, Inc. | -1.36 Million USD | -382.942% |
| Alpha Cognition Inc. | -13.77 Million USD | 52.252% |
| HST Global, Inc. | -146.21 Thousand USD | -4397.716% |
| CSL Limited | 2.64 Billion USD | 100.249% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -274.756% |
| Halberd Corporation | -79.67 Thousand USD | -8153.566% |
| Enzolytics Inc. | -2.17 Million USD | -202.095% |
| Agentix Corp. | -1.37 Million USD | -378.537% |
| Resverlogix Corp. | -3.61 Million USD | -82.164% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -107.354% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.771% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 6810.317% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 194.967% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -65.52% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -117.311% |
| AVAX Technologies, Inc. | -6.41 Million USD | -2.533% |
| Zenith Capital Corp. | -10.59 Million USD | 37.938% |
| Genscript Biotech Corporation | -95.47 Million USD | 93.112% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -28194.084% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -58.616% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -10780.286% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -227.967% |
| Kadimastem Ltd | -3.3 Million USD | -98.83% |
| Helix BioMedix, Inc. | -1.05 Million USD | -522.704% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -72.195% |
| BioStem Technologies, Inc. | -8.48 Million USD | 22.479% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1389.935% |
| LadRx Corporation | 400.44 Thousand USD | 1742.209% |
| Cell Source, Inc. | -5.32 Million USD | -23.583% |
| Regen BioPharma, Inc. | 1.02 Million USD | 742.507% |
| Regen BioPharma, Inc. | 1.02 Million USD | 742.507% |
| NovAccess Global Inc. | -4.76 Million USD | -37.887% |
| Affymax, Inc. | -14.42 Million USD | 54.409% |
| Itoco Inc. | -1.86 Million USD | -251.853% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -48.026% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -294.015% |
| Mobile Lads Corp. | -2.26 Million USD | -190.555% |
| CytoDyn Inc. | -49.84 Million USD | 86.806% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -8220.715% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2782.654% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -598.45% |
| SYBLEU INC | -180.3 Thousand USD | -3547.235% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -307.761% |
| International Stem Cell Corporation | -131 Thousand USD | -4919.932% |
| Bioxytran, Inc. | -4.28 Million USD | -53.647% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -12016.95% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -159.9% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 86.32% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -211.074% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -742.133% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -107.579% |
| Neutra Corp. | -233.46 Thousand USD | -2716.744% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 67.591% |
| PureTech Health plc | -65.69 Million USD | 89.99% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 69.078% |
| IXICO plc | -1.17 Million USD | -458.244% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 33.755% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 88.489% |
| CSL Limited | 2.64 Billion USD | 100.249% |
| Cellectis S.A. | -103.17 Million USD | 93.626% |